Navigation Links
Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
Date:4/18/2008

- Investigational Study Results Published in Journal of Clinical Oncology

Pave Way for Phase II Efficacy Trial -

NUTLEY, N.J., April 18 /PRNewswire/ -- A novel biweekly dosing schedule of Xeloda(R) (capecitabine) enabled safe delivery of higher daily doses in the treatment of advanced breast cancer, according to an investigational study published in the April 10, 2008 issue of the Journal of Clinical Oncology. The data showed that a seven-days-on/seven-days-off (7-on/7-off) regimen, called "dose dense," was generally well-tolerated up to 2,000 mg twice daily (4,000 mg/day), providing a potential alternative to the standard Xeloda dosing of 14 days on and seven days off (14-on/7-off).

"As we predicted using the Norton-Simon mathematical model -- the basis for the dose dense approach to therapy that was pioneered at MSKCC -- these results demonstrate that a biweekly regimen of capecitabine appears to be well-tolerated, at dosing levels that are higher than previously thought possible," said Tiffany A. Traina, M.D., a medical oncologist in the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York and lead author of the study. "We're currently conducting later-phase trials to determine the efficacy of this 7-on/7-off dosing schedule."

Efficacy of the 7-on/7-off schedule using Xeloda is being determined in a Phase II clinical trial program in patients with advanced breast cancer and is also being tested in combination with Avastin(R) (bevacizumab).

Breast cancer is the most common cancer among women, other than skin cancer. According to the American Cancer Society (ACS), about 182,460 women in the United States will be found to have invasive breast cancer in 2008. Breast cancer is the second leading cause of cancer death in women, after lung cancer -- about 40,930 women will die from the disease this year. Metastatic breast cancer, or cancer that has spread from the breast to othe
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015  Holographic Optical Technologies of ... of holographic medical imaging, is entering the world of ... Launching on April 20 th , 2015, the campaign ... The 8-inch and 22-inch displays will allow consumers to ... first time. In addition to the two displays, the ...
(Date:3/27/2015)... 27, 2015   Cypher Genomics, Inc., ... data showing that, compared to a panel of ... highly equivalent interpretations of whether certain genetic abnormalities ... in a fraction of the time. Cypher,s Mantis ... comprehensive genetic analysis in non-invasive prenatal testing (NIPT) ...
(Date:3/27/2015)... , March 27, 2015 XRpro Sciences, ... drug discovery and development services which features high ... pharmaceutical industry, announced financial results for the year ... C.  Tyson, Chairman of XRpro Sciences commented, "We ... transition from development stage to commercial stage in ...
Breaking Medicine Technology:Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4
... PARIS, October 24 Novexel, a speciality pharmaceutical,company ... antibiotics,designed to overcome the significant global problem of ... subject of five posters,at the joint annual meeting ... and the Infectious Disease Society of America (48th,annual ...
... - An Insulin Suppository Represents an Important Development ... Painless Alternative for Effective,Insulin Delivery, Oramed Pharmaceuticals, ... alternative drug delivery systems, announced today that it ... Council (MCC) to,begin conducting Phase 1A trials on ...
Cached Medicine Technology:Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting 2Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository 2Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository 3
(Date:3/28/2015)... 28, 2015 The California-based leading wig ... every customer shopping on UniWigs during the Easter Holidays ... a big promotion on April Fools’ Day. , As ... just around the corner. Easter Festival, with religious origins ... a major holiday after Christmas. The best wig provider, ...
(Date:3/28/2015)... IL (PRWEB) March 28, 2015 Centurion Service ... equipment auction on Thursday, April 2 at their Las Vegas ... Vegas, NV 89081. The sale, which consists of equipment from ... begin promptly at 9 a.m. PDT. , Buyers will ... and surgery equipment. “We are a one-stop-shop,” said Erik Tivin, ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... stiffness may not be necessary, according to research presented ... ( AOSSM ) Specialty Day. , “Our study compared ... with 25 who underwent an additional glenohumeral joint capsule ... surgery,” commented George Murrell MD, PhD, lead author from ...
(Date:3/28/2015)... 2015 Lately the student-athlete experience ... changes and proposals around the NCAA. In a March ... collegiate student-athletes across a spectrum of universities and sports ... challenges. The special panel consists of athletes who have ... from football, track and field, baseball, and volleyball. They ...
(Date:3/28/2015)... Aliso Viejo, California (PRWEB) March 28, 2015 ... have announced a new overlay entitled Scratches 5K from ... overlay grungy scratch effects to any media inside Final ... Film Studios. “StoryBoard Corporate saves time and is an ... any media using FCPX Overlay Scratches 5K's intuitive grunge ...
Breaking Medicine News(10 mins):Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2
... SCOTTSDALE, Ariz., Oct. 30 Changing Times,Vitamins, Inc., ... Las Vegas,has become a distributor for its primary ... tested, patent pending algae extract that has,been shown ... immune system. The beverage has no empty calories, ...
... Clinicians, Need for Detailed, Life-Saving Overdose,Information at the ... in November, TAMPA, Fla., Oct. 30 ... overdose references, Gold Standard Inc.,has re-launched ToxED ... toxicology reference addresses clinicians, need for,quick access to ...
... to acid in the mouth is the culprit, pediatric dentist ... its avalanche of candy is coming, making it the worst ... says a dentist who contends that parents can make a ... , "Parents need to know that frequency is far ...
... 30 Palomar Medical,Technologies, Inc. (Nasdaq: PMTI ... for cosmetic treatments, today announced financial,results for the ... the,quarter ended September 30, 2008 were $24.2 million, ... were royalty revenues, $1.0 million,were funded development revenues, ...
... Rally Residents to Eat Right, Move ... More and Milk Their Diets, WASHINGTON, Oct. ... of different fad diets -- which seem to go in and out ... out of three Americans -- including 22% of D.C. area residents --,remain ...
... SAN JUAN, Puerto Rico, Oct. 30 Triple-S,Management Corporation ... in,Puerto Rico, today announced record consolidated revenues for the ... million, or $0.29 per,diluted share, includes an after tax ... in net realized and unrealized losses on investments and,derivatives. ...
Cached Medicine News:Health News:Coors of Las Vegas Becomes New Distributor of RecoveryX 2Health News:Gold Standard Re-launches ToxED Clinical Toxicology Poisoning and Drug Overdose Reference 2Health News:Gold Standard Re-launches ToxED Clinical Toxicology Poisoning and Drug Overdose Reference 3Health News:Gold Standard Re-launches ToxED Clinical Toxicology Poisoning and Drug Overdose Reference 4Health News:Halloween Candy: It's Not How Much Kids Eat, It's When 2Health News:Halloween Candy: It's Not How Much Kids Eat, It's When 3Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 2Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 3Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 4Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 5Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 6Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 7Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 8Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 9Health News:Message to Washington D.C. Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Washington D.C. Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 2Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 3Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 4Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 5Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 6Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 7Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 8Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 9Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 10Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 11Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 12Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 13Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 14Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 15Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 16
18 gauge curved. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Straight, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tu...
Sharp tip with cutting edge bent to 50 degrees fits 19 gauge or 20 gauge instrument port, 20 gauge instrument port, 20 gauge x 25 mm tapering to 25 gauge x 4.76 mm. 10 per box....
Developed for oculoplastic procedures for corneal and scleral protection. Dimensions enable protector to rest on the sclera and not on the cornea. Easily removed with Bishop-Harmon Forceps. Individua...
Medicine Products: